Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This review consists of an explanation of the significance and sources of blood lipids and lipoproteins and an evaluation of the effects on triglycerides, cholesterol, and phospholipids of estrogens and progestagens taken combined or separately by normal or hyperlipidemic subjects. Normal blood contains alpha and beta lipoproteins (binding cholesterol and phospholipids) in morning, and chylomicrons (with dietary triglycerides) and prebeta-lipoproteins (with endogenous triglycerides) after a meal. Estrogens or combined pills raise triglycerides to 1.5 gm per 100 ml, the upper range of normal limits, due to an elevation of heavy prebeta-lipoproteins (0-12 SF). Th is elevation may be related to decreased lipoprotein lipase (post-heparin-lipolytic activity) seen in women taking estrogen. Heightened triglycerides have been observed in mixed and endogenous hyperlipidemia and types 1, 4, 5 (Frederickson classification), but not essential or type 2 hyperlipidemia. Progestogens lower triglycerides and raise lipoprotein lipase in normal subjects and in those with endogenous hyperlipidemia type 5. Results of studies of total cholesterol are variable: androgenic progestogens decrease cholesterol, but other progestagens increased it in some studies. A norethisterone and ethinyl estradiol combination has been shown to raise high- and very high-density lipoproteins, cephalin and lecithin, but to depress lyso-le cithin. Besides altered lipoprotein lipase, these lipoprotein changes c ould be due to elevated insulin, cortisol, thyroxin, or growth hormone, or their protein carriers.
Sem Hop Paris 1973 Oct 26
PMID:[Study of metabolism of circulating lipids during oral contraception]. 1230 67

Soybeans and hops have been traditionally used as a natural estrogen replacement therapy and their major active ingredients, isoflavones and prenylflavanones, are known to have estrogenic/antiestrogenic effects depending on the target organ. However, their potential benefits are still subject to controversies. The present study investigated the dual effect of soy isoflavones plus hop prenylflavanones (Soy-Hop) on bone loss and metabolic dysfunction under estrogen deficient condition. Rats were sham-operated (n = 10) or ovariectomized (OVX; n = 40) and then fed a high-fat diet (HFD) to develop hyperlipidemia in OVX rats within the experimental period of 8 weeks. The OVX/HFD rats were assigned to four groups to receive different doses of Soy-Hop (0, 30, 100, and 300 mg/kg) by oral gavage for 8 weeks. High-dose Soy-Hop significantly suppressed OVX/HFD-induced increases in food intake, body weight gain, fat mass, and circulating levels of leptin, adiponectin, LDL-cholesterol, total cholesterol, triglycerides, glucose, and insulin. High-dose Soy-Hop also attenuated OVX/HFD-induced elevation of osteocalcin, alkaline phosphatase, and CTX in plasma and RANKL/OPG gene expression ratio in femur. These findings were confirmed visually by confocal analysis of GLUT4 translocation in soleus muscle cells and micro-computed tomography scanning of the distal femoral epiphysis, respectively. These results suggest that Soy-Hop may have potential to ameliorate estrogen deficiency-related alterations in both metabolism and bone quality, at least in part, by hormonal factors secreted by adipocytes.
 ...
PMID:Soybean-Hop Alleviates Estrogen Deficiency-Related Bone Loss and Metabolic Dysfunction in Ovariectomized Rats Fed a High-Fat Diet. 2977 36


<< Previous 1 2